Patients need to understand the journey of presbyopia-correcting lenses

ByAlex Young

Fact checked byChristine Klimanskis, ELS

BOSTON — The use of advanced presbyopia-correcting implants is a journey for the patient, according to a speaker at the American Society of Cataract and Refractive Surgery meeting.

“Presbyopia-correcting implants are not a lot different than the traditional implant journey,” Vance Thompson, MD, said in a prerecorded presentation.

Graphic distinguishing meeting news — The use of advanced presbyopia-correcting implants is a journey for the patient, according to a speaker at the American Society of Cataract and Refractive Surgery meeting.

This means performing the necessary presurgical calculations and surgery to achieve 20/20 vision, and if a patient falls short of that goal, it is time to fine-tune at 3 months. With traditional implants, fine-tuning is done with glasses. With advanced implants, it is done with laser vision correction. YAG laser capsulotomy and tear film management may be done with either type of implant, Thompson said.

The first 3 to 6 months of the journey is optimizing the image to 20/20 in each eye followed by 3 to 6 months of neural adaptation.

“At the end of that 9- to 12-month journey, you’ll have some of the world’s most sophisticated optics in your eyes with a high level of satisfaction as long as you’re patient and understand it’s a journey,” Thompson said.

Published by:

Sources/Disclosures

Collapse

Source:

Thompson VM. Advanced implant journey. Presented at: American Society of Cataract and Refractive Surgery meeting; April 5-8, 2024; Boston.

Disclosures: Thompson reports having financial disclosures for 2EyesVision, AdOM, AI Optics, Alcon, Allotex, Avisi Technologies, Balance Ophthalmics, Bausch + Lomb, BVI, Carl Zeiss Meditec, Centricity Vision, Crystilex, D&D Biopharmaceuticals, DelSiTech, Euclid Vision Group, Expert Opinion, eyeBrain Medical, Eyedetec, Eyesafe, Fontana Biosciences, Foresight Robotics, Glaukos, iVeena Delivery Systems, Johnson & Johnson, LayerBio, Lightfield Medical, Medevise Consulting, Melt Pharmaceuticals, NanoDrops, Nordic Pharma, Ocular Therapeutix, Oculotix, ORA, Rayner, Reopia Optics, RxSight, Singular Strategies, STAAR Surgical, StepWise Medical, Stuart Therapeutics, Tarsus Pharmaceuticals, TearClear, TearOptix, TherOptix, TreeHouse Health, True North Therapeutics, Trukera Medical, Vance Thompson Vision, Visionary Ventures and Visus.

American Society of Cataract and Refractive Surgery Meeting

Read more

Patients need to understand the journey of presbyopia-correcting lenses

Related Content